Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

The combination of durvalumab and tremelimumab-actl conferred a sustained OS benefit at 4 years among patients with unresectable hepatocellular carcinoma, according to phase 3 trial results from the ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies ...

SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed.

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...

In the final overall survival analysis of the phase 3 CARES-310 trial, frontline camrelizumab plus rivoceranib continued to show clinically meaningful survival benefits vs sorafenib for hepatocellular ...

The study’s senior author discusses how the combined mechanisms of action produced benefit in progression-free survival. Results presented today at the American Society of Clinical Oncology ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly ...